Nalaganje...
The root cause of drug resistance in HER2-positive breast cancer and the therapeutic approaches to overcoming the resistance
HER2 is a well-known oncogenic receptor tyrosine kinase. HER2 gene amplification occurs in about 20% of breast cancer (BC), which leads to overexpression of HER2 protein, known as HER2-positive BC. Inhibitors of HER2 have significantly improved the prognosis of patients with this subset of BC. Since...
Shranjeno v:
| izdano v: | Pharmacol Ther |
|---|---|
| Glavni avtor: | |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2020
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7855784/ https://ncbi.nlm.nih.gov/pubmed/32898548 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.pharmthera.2020.107677 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|